Sujin Lee, APRN
Nurse Practitioner · Scottsdale, AZNPI 1053980383
Payments from drug & device makers
Across 20 payments — averaging $97.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$474
- Cequr Corporation$312
- Dexcom, Inc.$174
- Tandem Diabetes Care, Inc.$169
- Corcept Therapeutics$151
- AbbVie$146
- plus $534 from 5 others
What the payments were for
- Food & beverage$1,959100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 6 | $474 |
| Cequr Corporation | 1 | $312 |
| Dexcom, Inc. | 3 | $174 |
| Tandem Diabetes Care, Inc. | 3 | $169 |
| Corcept Therapeutics | 1 | $151 |
| AbbVie | 1 | $146 |
| Bayer | 1 | $125 |
| Madrigal Pharmaceuticals | 1 | $122 |
| AstraZeneca | 1 | $114 |
| Lilly USA, LLC | 1 | $113 |
| W. L. Gore & Associates, Inc. | 1 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$312
- Korlym$151
- DALVANCE$146
- Ozempic$125
- Kerendia$125
- RYBELSUS$123
- REZDIFFRA$122
- DEXCOM G7 GSS (161)$121
- FARXIGA$114
- MOUNJARO$113
- t:slim X2 Insulin Pump with Control-IQ$104
How this compares
$1,959 in reported general payments places this provider in the 85th percentile of 1,719 nurse practitioner providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $11,190 |
| Humalog Kwikpen U-100Insulin Lispro | 51 | $8,704 |
| TradjentaLinagliptin | 12 | $7,276 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $5,417 |
| Novolog FlexpenInsulin Aspart | 31 | $4,238 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 26 | $4,212 |
| Ultra-Fine Micro Pen NeedlePen Needle, Diabetic | 70 | $4,131 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,236 |
| Novofine 32Pen Needle, Diabetic | 55 | $3,128 |
| Insulin Aspart FlexpenInsulin Aspart | 20 | $2,714 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 26 | $1,537 |
| Insulin Glargine-Yfgn | 21 | $1,486 |
| Alcohol SwabsAlcohol Antiseptic Pads | 13 | $51 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Scottsdale
- Kristen HerzogScottsdale$162K
- Kelley RoneScottsdale$29K
- Jill StudyScottsdale$24K
- Jennifer BarbosaScottsdale$21K
- Jessica LoweryScottsdale$16K
- Ronald OrdasScottsdale$8K
- Theresa LongoScottsdale$8K
- Samantha DeberryScottsdale$8K
- Meagan GruwellScottsdale$7K
- Ann MooreGlendale$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.